Table 2.
Clinicopathological characteristics of study population.
| Clinicopathological characteristics | Control | Recurrence | |
|---|---|---|---|
| Tumour status | |||
| T1 | 25 (67.6) | 12 (32.4) | P = 0.017 |
| T2 | 34 (47.9) | 37 (52.1) | |
| T ≥ 3 | 8 (33.3) | 16 (66.7) | |
| Nodal status | |||
| N0 | 40 (71.4) | 16 (28.6) | P < 0.001 |
| N1 | 16 (41.0) | 23 (59.0) | |
| N2 | 6 (27.3) | 16 (72.7) | |
| N3 | 5 (31.3) | 11 (68.7) | |
| TNM Staging | |||
| I | 22 (68.8) | 10 (31.2) | P = 0.001 |
| II | 30 (58.8) | 21 (41.2) | |
| III | 14 (28.6) | 35 (71.4) | |
| Histological grade | |||
| 1 | 18 (81.8) | 4 (18.2) | P = 0.004 |
| 2 | 15 (40.5) | 22 (59.5) | |
| 3 | 33 (45.2) | 40 (54.8) | |
| Nottingham Prognostic Index | |||
| Good | 19 (76.0) | 6 (24.0) | P = 0.003 |
| Moderate | 30 (53.6) | 26 (46.4) | |
| Poor | 17 (34.7) | 32 (65.3) | |
| Vascular invasion | |||
| No | 34 (58.6) | 24 (41.4) | p = 0.078 |
| Yes | 31 (43.1) | 41 (56.9) | |
| Histology | |||
| Ductal | 56 (47.5) | 62 (52.5) | P = 0.110 |
| Others | 11 (68.8) | 5 (31.2) | |
| ER Status | |||
| Negative | 15 (53.6) | 13 (46.4) | P = 0.638 |
| Positive | 51 (48.6) | 54 (51.4) | |
| PR status | |||
| Negative | 19 (43.2) | 25 (56.8) | P = 0.296 |
| Positive | 47 (52.8) | 42 (47.2) | |
| Her2 status | |||
| Negative | 53 (60.2) | 35 (39.8) | P = 0.054 |
| Positive | 12 (40.0) | 18 (60.0) | |
G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated.
T1: ≤ 2 (cm); T2: 2< but ≤5 (cm); T3: >5 (cm); T4: invasion of chest wall and skin.
N0: no regional lymph node metastasis; N1: metastasis involving 1–3 lymph nodes; N2: metastasis involving 4–9 lymph nodes; N3: metastasis involving ≥10 lymph nodes.
Nottingham Prognostic Index = (0.2xS)+N + G, where S is tumour size in centimetre, N is nodal status, G is histological grading, Good <3.4, Moderate 3.4<x < 5.4, Poor= >5.4.
ER: estrogen receptor.
PR: progesterone receptor.
Her2: human epidermal growth factor receptor 2.